Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Invested Capital (2017 - 2025)

Crinetics Pharmaceuticals has reported Invested Capital over the past 9 years, most recently at $992.1 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 25.11% year-over-year to $992.1 million; the TTM value through Dec 2025 reached $992.1 million, down 25.11%, while the annual FY2025 figure was $992.1 million, 25.11% down from the prior year.
  • Invested Capital for Q4 2025 was $992.1 million at Crinetics Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $1.3 billion in Q4 2024 and troughed at $149.5 million in Q1 2021.
  • A 5-year average of $610.4 million and a median of $462.6 million in 2022 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: plummeted 34.19% in 2023 and later soared 226.92% in 2024.
  • Year by year, Invested Capital stood at $331.9 million in 2021, then fell by 4.7% to $316.3 million in 2022, then surged by 70.43% to $539.1 million in 2023, then skyrocketed by 145.74% to $1.3 billion in 2024, then fell by 25.11% to $992.1 million in 2025.
  • Business Quant data shows Invested Capital for CRNX at $992.1 million in Q4 2025, $1.1 billion in Q3 2025, and $1.2 billion in Q2 2025.